The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is ...

Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative ...

Torrent Investments, a promoter entity of Torrent Pharmaceuticals, has offloaded a total of 99.44 lakh shares or 2.94 per ...